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Abstract 
The diagnosis, prognostic factors, and opti-
mal management of primary breast lymphomas
(PBL) is difficult. Seven patients recorded at
the Geneva Cancer Registry between 1973-1998
were reviewed. Five patient had diffuse large B-
cell lymphoma, one a follicular lymphoma and
one a MALT-lymphoma. All patients had clinical
and radiological findings consistent with breast
cancer and underwent mastectomy, which is not
indicated in PBL. Diagnosis should be estab-
lished prior to operative interventions, as fine
needle aspiration missed the diagnosis for one
patient and intra-operative frozen sections for 3
patients  in  our  study.  Five-year  and  10-year
overall survivals were 57% and 15%, respective-
ly. Of the 3 patients who died from PBL, 2 had
tumors that were Bcl-2 positive but Bcl-6 nega-
tive. All 3 surviving patients have positive Bcl-2
and  Bcl-6  immunostaining,  which  could  be
important prognostic factors if confirmed by a
larger study.
Introduction
The breast is one of the least common pri-
mary  extranodal  sites  for  malignant  lym-
phomas.  A  variety  of  pathological  subtypes
have been reported. The frequency with which
the different subtypes of primary lymphoma of
the  breast  occur  is  difficult  to  determine,
because  both  terminology  and  classification
vary among the relatively small case series that
have been reported. There is general agree-
ment, however, that these lymphomas are usu-
ally of Non-Hodgkin’s lymphoma (NHL) histol-
ogy.
1 They account for 0.04-0.5% of all breast
neoplasms and less than 1% of all NHL.
2
NHL is a potentially systemic disease; there-
fore, appropriate management must take this
into account.
1 Clinically and pathologically, pri-
mary lymphomas of the breast must be distin-
guished from both benign lymphoid infiltrates
and  non-lymphoid  neoplasms  of  the  breast.
Since the breast normally contains some lym-
phoid tissue and functions during lactation as
part  of  the  mucosal  immune  system,  lym-
phomas  in  this  site  may  be  related  to  lym-
phomas of mucosa-associated lymphoid tissue,
so-called MALT lymphoma. Primary breast lym-
phoma (PBL) can still be misdiagnosed as car-
cinoma,  a  particular  point  of  interest  for
pathologists and clinicians. In addition, there
is a lack of consensus about its treatment and
prognostic factors. The purpose of this study is
to evaluate clinical presentation and patholog-
ical features, diagnostic difficulties and poten-
tial prognostic markers of this rare tumor.
Materials and Methods
The  data  were  derived  from  the  Geneva
Cancer  Registry,  which  includes  information
regarding  all  cases  of  malignant  neoplasms
occurring  in  the  population  of  the  region
(approximately 420,000 inhabitants). The reg-
istry collects information from various sources
and is considered accurate, as attested by its
very low percentage (<2%) of cases recorded
from death certificates only.
3 Individual clinical
files from all university public hospitals are sys-
tematically  consulted  and  inquiry  forms  are
addressed  regularly  to  physicians  for  patients
treated in the private sector. Trained registrars
systematically abstract data from medical and
laboratory records. Physicians regularly receive
questionnaires to secure missing clinical and
therapeutic data. Death certificates are consult-
ed systematically. Recorded data include socio-
demographic information, method of discovery,
type  of  confirmation,  tumor  characteristics
(coded  according  to  the  International
Classification of Diseases for Oncology),
4 stage
of disease at diagnosis, treatment during the
first six months after diagnosis, survival status,
and cause of death. 
The registry regularly assesses survival rate
index. In brief, it refers to the date of confirma-
tion of diagnosis or the date of hospitalization if
it preceded the diagnosis and was related to the
disease. In addition to passive follow-up (routine
examination of death certificates and hospital
records), an active follow-up is performed rou-
tinely each year using the files of the Cantonal
Population Office in charge of the registration of
the resident population. Finally, cause of death is
established  from  clinical  records  and  coded
according  to  the  World  Health  Organization’s
classification.
5
In this study we included all cases of PBL
diagnosed between January 1973 and December
1998 among the resident population. Additional
clinical information was obtained from a retro-
spective review of all the patient charts. 
Pathological  diagnosis  of  primary  breast
lymphoma was based on the following strict
criteria as described by Wieseman and Liao in
1972: 1) an adequate pathological specimen;
2) a close association of mammary tissue and
lymphomatous infiltrate; 3) no evidence of dis-
seminated lymphoma at the time of diagnosis;
and  4)  the  presence  of  ipsilateral  axillary
nodes  was  acceptable  if  they  occurred  con-
comitantly  with  the  primary  lesion.  Staging
was based on the WHO classification 2001.
6 In
all  patients,  the  pathological  diagnosis  was
established on excisional biopsy or mastecto-
my  specimen.  Original  hematoxylin-eosin-
stained sections and formalin-fixed, paraffin-
embedded tissue were available in all cases.
Histological review of the microscopic slides
was  performed  by  some  of  the  authors
(MFP/ATV).  Extensive  immunohistochemical
studies were performed.
Histology and immunohisto-
chemistry
Conventional  histology  included  hematox-
ilin eosin, Giemsa, and silver stain of all avail-
able tissue blocks. Immunostaining was per-
formed  using  the  listed  antibodies  with  a
streptavidine-biotin  peroxidase  system.
Antigen retrieval, if necessary, was carried out
either by microwaving or pressure cooking in
ethylenediamine  tetraacetic  buffer  (pH  2.5).
Rare Tumors 2009; volume 1:e14
Correspondence:  Olivier  Julen,  Department  of
Gynecology  and  Obstetrics,  Geneva  University
Hospital, 1211 Geneva 4, Switzerland
E-mail: olivier.julen@hcuge.ch
Anne-Thérèse Vlastos, Department of Gynecology
and Obstetrics, Geneva University Hospital, 1211
Geneva 4, Switzerland. E-mail: anne-therese.vlas-
tos@hcuge.ch
Key words: lymphoma, breast, cancer, bcl6, bcl2.
Acknowledgments: we thank the technicians of
the  Department  of  Clinical  Pathology  for  their
work with immunostaining. We also thank the
registrars of the Geneva Cancer Registry for col-
lecting additional data on this subset of patients.
Received for publication: 30 June 2009.
Accepted for publication: 1 July 2009.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0)
©Copyright O. Julen et al., 2009
Rare Tumors 2009; 1:e14
doi:10.4081/rt.2009.e14[Rare Tumors 2009; 1:e14] [page 37]
The work-up included CD3, CD4, CD5, CD8,
CD20, CD21, CD23, CD30, CD45, CD68, CD79a,
MIB1, pan-cytokeratine, Bcl-2 and Bcl-6. If not
otherwise  mentioned,  these  antibodies  were
from Dako, Copenhagen. The SPSS software
(SPSS 10 version Inc., Chicago, IL.) was used
for  statistical  analysis.  Descriptive  statistics
were performed to assess the frequency distri-
bution. We calculated disease-specific and dis-
ease-free  interval  probabilities  using  the
Kaplan-Meier  method.
7
Results
Since its creation in 1970, the registry has
recorded over  7,800 women with breast malig-
nancies.  Only  9  patients  were  initially  diag-
nosed  and  recorded  as  primary  breast  lym-
phoma, representing less than 0.1% of all malig-
nant breast tumors. However, there were only 7
true PBL after histological review. In 2 women,
clinical investigations performed at diagnosis
were insufficient to definitively conclude that
the lymphoma occurred primarily in the breast.
Patients’ characteristics
Patients’  and  tumor  characteristics  are
described in Table 1. The median age at diag-
nosis was 65 years (range 39-86); most were in
the seventh decade of life (4 patients, 57%).
Three  patients  (43%)  had  left-breast
involvement and 4 (57%) right-breast involve-
ment. None had bilateral involvement. Clinical
lesions  were  located  predominantly  in  the
upper  outer  quadrant  (UOQ)  in  2  (29%)
patients, in the upper outer and inner quad-
rant in 2 (29%), in the lower outer quadrant
(LOQ) in one (14%) and involved the whole
breast  in  one  patient  (14%).  Four  patients
(57%) had no clinical axillary involvement. All
patients sought consultation for breast related
symptoms and presented with a palpable mass.
Only one patient reported pain, described as
located in the homolateral shoulder; however,
the whole breast was involved in this case. No
malignant lymphoma was suspected on clinical
examination, nor in complementary investiga-
tions. In particular, mammography examina-
tion before surgery was suggestive of breast
carcinoma in all cases (100%). 
First diagnosis was breast carcinoma in 6
out of 7 cases (86%) and inflammatory breast
carcinoma  in  one  case  (14%).  Fine  needle
aspiration (FNA) was performed in 2 (29%)
cases,  both  suggestive  of  breast  carcinoma.
Primary breast lymphoma was diagnosed after
surgical excision in all cases, with frozen sec-
tion diagnosis for 3 cases. Frozen section diag-
noses  revealed  lymphoma  in  2  cases  and  a
malignant non-differentiated tumor. 
Pathology
Table 2 summarizes pathological character-
istics  among  primary  breast  lymphoma
patients. The average tumor size at diagnosis
varied  from  2  cm  to  6.3  cm  in  the  greatest
diameter (mean, 4.5 cm) (Table 1). The sec-
tion  presented  with  homogeneous  fish-flesh
surface with occasional hemorrhagic or necro-
sis foci. For small tumors, margins were regu-
lar and pushing, for larger, irregular and stel-
late.  Fibrosis  or  sclerosis  surrounding  the
tumor mass may suggest a medullary carcino-
ma of the breast or a benign process. Under
light microscopy, the tumor masses were poor-
ly  circumscribed,  infiltrating  the  mammary
lobules,  and  surrounded  mammary  ducts.
Diffuse large B-cell lymphoma, or DLBCL, was
the most common entity, (5 cases; 71%). Large
blastic B cells replaced the normal architecture
of the underlying breast in a diffuse pattern
and  broad  or  fine  bands  of  sclerosis  were
observed. The morphological variant was cen-
troblastic lymphoma for all of the masses. The
most common DLBCL were composed of medi-
um-sized to large lymphoid cells with general-
ly basophilic cytoplasm. Nuclei were character-
ized by oval to round vesicles, fine chromatin
and  2-4  membrane  bound  nucleoli.  In  some
cases,  the  cells  were  multilobated.  Centro-
blastic variant of diffuse large B-cell lymphoma
was monomorphic in one case and polymor-
phic in the remaining  cases. One case was
diagnosed with grade III follicular lymphoma
(Figure 1). The remaining case was an extra-
nodal  marginal  zone  B-cell  lymphoma  MALT
lymphoma. The characteristic marginal zone B
cells had small to medium-sized, slightly irreg-
Article
Table 1. Clinical staging under presumption of carcinoma.
N. Age Working Clinical  Side Location Size TNM Primary Secondary CR Time to D F S  Cause of
yr classification presentation cm staging treatment treatment death years of death
1 86 MALT Periartritis R All breast 6.5 T4d N2 Mx Patey Rx refused Yes 5 years 5  PBL
2 78 Follicular  Breast mass R UO+I NA T3 N1 Mx Patey Ch refused No 2 months progressionPBL
3 74 DLBCL Breast mass L UO 5 T3 N0 Mx Mastectomy  No No 15 days progressionPBL
4 62 DLBCL Breast mass L UO 3 T2 N0 Mx Patey No Yes 5 years 5  Cardiac
5 71 DLBCL Breast mass R UO+I 5.4 T3 N1 Mx Patey Ch: CHOP Yes / *7,5 Alive
6 39 DLBCL Breast mass R NA 2 T2 N0 Mx LAND Rx Yes / *16,5 Alive
7 44 DLBCL Breast mass L LO 5 T3 N0 Mx Patey Ch: CHOP Yes / *4,5 Alive
UO: upper outer quadrant; UI: upper inter quadrant; LO: lower outer quadrant; R: right; L: left; TNM: classification by Tumor Node Metastasis; Age*: years; MALT: MALT lymphoma; Follicular: follicular lymphoma;
DLBCL: diffuse large B-cell lymphoma; LAND: lumpectomy and axillary dissection; Pathey: mastectomy and axillary dissection; DSF: disease free survival; CR: complete response.
Table 2. Pathological characteristics including immunochemical studies. Patient Direct
N. Age Working Keratine LCA CD3 CD20 CD79 MiB1 Bcl-2 Bcl-6 MiB1
yr classification
1 86 MALT ++ - + + 60% +- 60%
2 78 Follicular  -+ - + +30% -+ 30%
3 74 DLBCL ++ - + + 50% +- 50%
4 62 DLBCL ++ - + + / - -/
5 71 DLBCL -+ - + +80% ++ 80%
6 39 DLBCL -+ + + +80% ++ 80%
7 44 DLBCL ++ - + + 90% +- 90%
UO: upper outer quadrant; UI: upper inter quadrant; LO: lower outer quadrant; R: right; L: left; TNM: classification by Tumor Node Metastasis; Age*: years;  MALT: MALT lymphoma; Follicular: follicular lymphoma;
DLBCL: diffuse large B-cell lymphoma.[page 38] [Rare Tumors 2009; 1:e14]
ular  nuclei  with  moderately  dispersed  chro-
matin and inconspicuous nucleoli, resembling
those  of  centrocytes.  They  had  a  relatively
abundant,  pale  cytoplasm.  The  glandular-
epithelium  was  invaded  and  destroyed  by
aggregates of lymphoma cells resulting in so-
called lymphoepithelial lesions (Figure 2). 
Four DLBCL showed additional histological
features  of  MALT  (lymphoepithelial  lesions)
(Figure 3). Our last 2 cases showed no lym-
phoepithelial lesions but clearly showed ductal
invasion by lymphoma cells (Figure 4).
Immunophenotype 
Immunohistochemical studies are reported in
Table 2. As expected, DLBCL expressed the pan-
B markers CD20 and CD79. Bcl-2 was positive in
4 cases (80%) and nuclear expression of Bcl-6 in
2 cases (40%). MiB1 was highly expressed indi-
cating a high proliferative rate (up to 90%) in all
cases. The follicular lymphoma expressed the
pan-B markers CD20 and CD79 as well as Bcl-6.
Bcl-2 protein was expressed in the majority of
the reported cases, ranging from nearly 100% in
grade I to 75% in grade III however, cutaneous
follicular lymphoma is frequently Bcl-2 negative.
MiB1 was expressed in 30% of the cells. The
MALT lymphoma expressed CD20 and CD79 as
well as Bcl-2.
Treatment 
Various  treatment  strategies  were  used
according  to  available  data.  Treatments  are
reported in Table 1. Surgery was initially per-
formed because of the initial clinical impres-
sion of mammary carcinoma. Surgeries con-
sisted of mastectomies associated with an axil-
lary lymph node dissection for 6 patients and a
breast conserving surgery for one patient with
a small size (2 cm) lesion. The Levels I and II
axillary lymphatics were included within the
breast or chest-wall fields; 3 of the 6 performed
were positive (50%). 
The treatment proposed after surgery was
chemotherapy in 3 cases (43%), of whom one
(14%)  refused  and  radiotherapy  in  2  cases
(29%), which was also refused by one patient
(14%). The last 2 cases (29%) were treated
with surgery alone. One patient had a mastec-
tomy  and  axillary  dissection.  The  second
patient had a simple mastectomy and did not
receive adjuvant therapy because of her poor
condition.  None  of  the  cases  received  com-
bined modality approaches.
Outcome
Median follow-up was 5.8 years (range: 0.15-
16).  Of  the  7  patients,  5  achieved  complete
response after therapy (Table 1). Two patients
never achieved complete response and died of
disease progression. In one of these patients
progression  was  observed  to  the  brain  and
skin. The other, because of her poor medical
condition, died two weeks after surgery. One
relapsed  after  five  years  (skin)  and  subse-
quently died of lymphoma. At time of the last
follow-up, 3 were alive. One died of other caus-
es (cardiovascular disease). Five and 10-year
overall  survival  rates  were  57%  and  15%,
respectively. Of the 3 patients who died from
their PBL, 2 had positive Bcl-2 immunostain-
ing  (66%) but negative Bcl-6 immunostaining
(66%). On the other hand, of the 3 patients still
alive,  all  had  positive  Bcl-2  immunostaining
and 2 positive Bcl-6 immunostaining (66%).
Treatment modalities and their corresponding
effect on mortality are presented in Table 1.
Discussion 
In the present study we evaluated all patients
who  presented  with  primary  lymphomatous
involvement of the breast over a 26-year period
at our institution. Only the patients who satis-
fied  the  strict  criteria  of  PLB  according  to
Wiseman and Liao were analyzed for this study
to avoid the potential inclusion of patients with
secondary breast involvement of NHL.
2The most
frequent clinical scenario is that of a unilateral
breast mass presenting in a middle-aged woman
(median age: 55-60 years).
1,8-10 In our series we
found  an  older  median  age:  65  years  (39-86
years),  as  already  described,  whereas  some
authors find a younger median age.
11 The right
breast  was  reported  to  be  most  frequently
involved.
1,8-11 Only a few series report the oppo-
site and another had no predominant site.
12 Five
to 25%
2,13 of reported cases were simultaneously
bilateral  at  presentation,
8,10,12 nevertheless  no
such case is reported in our series. We were par-
ticularly  interested  in  the  method  by  which
these tumors were detected and hypothesized
that increased knowledge and the current wide-
spread  use  of  mammography  as  a  screening
method for breast carcinoma may increase the
detection  of  breast  lymphoma.  Hemato-
poietic neoplasms involving the breast, although
less common than breast carcinoma, are often
clinically  indistinguishable  from  other  breast
tumors.  Microscopically,  these  tumors  can
mimic primary carcinoma of the breast, espe-
cially in limited material such as fine needle
aspirations (FNA). In 2 patients with FNA in our
series, cytology was interpretated as carcinoma.
In the 3 patients with frozen section diagnosis,
only  one  (the  follicular  lymphoma  case)  was
Article
Figure 1. Follicular lymphoma. (a) Follicular aspect: HE (x100); (b) large transformed
cells with one to three peripheral nucleoli: Giemsa (x200); (c) B cells with follicular
arrangement: CD79 (x50); (d) B cells with follicular arrangement: CD79 (x100); (e) reac-
tive T cells surrounding the B cells with follicular arrangement: CD3(x50); (f) Bcl-6
staining (x200).[Rare Tumors 2009; 1:e14] [page 39]
diagnosed correctly. FNA misdiagnosis has been
reported by several authors.
12
However, breast carcinoma is not the only
pitfall. Diabetic mastopathy (DM) may be over-
interpreted as lymphoma. DM, which has been
described in both diabetic patients and non-
diabetic  patients,  generally  demonstrates
fibrocystic change with dense stromal fibrosis
and  an  extensive  perivascular  infiltrate  of
small B-lymphocytes. However, there is no cur-
rent evidence that DM is a precursor lesion to
PBL.
8,13 Traditionally a surgical approach to the
treatment of patients’ PBL has been adopted,
2
even if mastectomy could be avoided in most
patients,
15 and treatment confined to chemo-
therapy and radiation therapy appropriate for
the histological type. In our series, all patients
underwent a surgical treatment. It is important
to  underline  that  all  mastectomies  in  our
series were performed due to the initial clini-
cal  and/or  pathological  diagnosis  impression
(frozen  section  or  FNA)  of  adenocarcinoma.
Similarly, although there have been reports of
radiation therapy alone for patients with PBL,
16
patients  with  intermediate-grade  and  high-
grade lymphomas of the breast are best treated
with chemotherapy or with combined chemo-
therapy and radiation therapy.
10
Published reports on the treatment outcome
for PBL range from equivalent to worse prog-
nosis for PBL compared to other non-Hodgkin’s
lymphomas (NHL).
1,2 Confounding the matter
are the different definitions of PLB used by dif-
ferent authors. Some consider the lymphoma
to be PBL if the patient presents with com-
plaints relating to the breast or if the main
tumor  mass  is  in  the  breast.
1,12 Others  use
more  strict  definitions  of  PBL.
2,16 Different
pathological  types  of  breast  lymphoma  have
also been reported by different investigators at
least partially because of different histological
criteria used.
9,12
Cohen et al. studied both primary and sec-
ondary breast lymphomas with a broad panel of
T- and B-cell markers using paraffin-embedded
tissue  and  the  avidin-biotin  immunoperoxi-
dase method. Cases of PBL were further tested
to  determine  light  and  heavy  chain  type.
Thirty-five cases were analyzed, including 16
primary  lymphomas.  Diffuse  large  cell  lym-
phoma was present in 10 of 16 primary and 14
of  18  secondary  cases.  Lymphoepithelial
lesions in ducts and lobules and frequent vas-
cular involvement were found in both primary
and  secondary  cases.  Immunohistochemistry
studies on 13 tumors revealed all of the pri-
mary tumors to be B-cell in origin, except for
one case of primary T-cell lymphoma; to the
authors' knowledge, this represents the first
description of this entity. Fifteen of 17 second-
ary tumors exhibited B-cell markers and one of
17 exhibited T-cell markers; in only one case
could lineage not be determined.
17 Among pri-
mary  B-cell  cases,  IgM  was  found  to  be  the
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Figure 4. Primary breast lymphoma with-
out  lymphoepithelial  lesion.  (a)
Proliferation  index:  MiB1  (x200)  (80%
positive);  (b)  HE  (x100);  (c)  mammary
gland: keratin (x200).
Figure  3.  Lymphoepithelial  lesions.  (a)  Lymphoepithelial  lesion:  HE  (x50);  (b)  lym-
phoepithelial lesion: HE (x100);(c) mammary gland: keratin (x200); (d) mammary gland
infiltrated by B cells: CD20 (x200).
Figure 2. Destruction of the glandular tis-
sue epithelium by aggregates of lymphoma
cells.    (a)  Mammary  gland  infiltrated  by
lymphoma cells: HE (x400); (b) mammary
gland infiltrated by B cells: CD20 (x400);
mammary gland: Keratin (x400). [page 40] [Rare Tumors 2009; 1:e14]
most frequent heavy chain type; IgA reactivity
was found in one case only.
18
In  our  series,  the  World  Health  Organiz  -
ation  Classification  of  Tumors  was  used.
6
Diffuse large B-cell lymphoma (DLBCL) was
the  most  common  diagnosis  (71%)  and  all
cases  were  of  B-cell  phenotype.  Although
there  was  some  variation  in  histological
appearance from patient to patient, the char-
acteristics  of  large  B-cell  breast  lymphoma
were  not  distinctive  and  resembled  DLBCL
occuring at other sites. In addition, we report-
ed  a  follicular  lymphoma  and  a  MALT  lym-
phoma. Lamovec and Jancar first reported that
some PBLs had features of MALT lymphoma.
Subsequently,  several  series  have  reported
MALT lymphoma as part of the spectrum of
PBL, comprising 0-64% of all PBL.
9,10,18,19
DLBCL  are  a  heterogeneous  group  of
tumors, varying in cellular content, phenotype,
cytogenetics, site of presentation and natural
history of disease. They represent the most fre-
quent type of NHL, accounting for 30-40% of
adult NHL.
20 Although approximately half of the
patients with DLBCL can be cured by conven-
tional chemotherapy, the remainder will die of
their disease. Identification of patients at pres-
entation who are unlikely to be cured by stan-
dard therapy is a key step in developing new
treatment  strategies.  At  present,  the  most
effective tool for the identification of prognos-
tic subgroups is the International Prognostic
Index  (IPI),
21 which  is  calculated  using  age,
Ann Arbor Stage, number of extranodal sites,
performance  status  (Eastern  Cooperative
Oncology Group (ECOG) scale) and serum lac-
tate  dehydrogenase  (LDH),  all  of  which  are
independent  risk  factors.  Several  molecular
abnormalities,  such  as  Bcl-2
22 and  survivin
23
expression and p53 mutations,
24 were identi-
fied as prognostic indicators of DLBCL. Bcl-2
expression  was  reported  to  correlate  with
reduced  disease-free  survival  (DFS),
22 but  it
only  predicted  reduced  overall  survival  (OS)
for patients with DLBCL in one of the reported
studies.
22 The Bcl-2 protein is expressed in a
significant proportion of DLBCLs, either as a
consequence  of,  or  independently  of,  the
translocation-t(14;18).
21,22This has been shown
in  a  number  of  studies  to  have  an  adverse
effect  on  survival
21,22 and  is  the  most  widely
accepted  cellular  prognostic  factor.  In  our
study, Bcl-2 was expressed in 5 cases (71.4%).
In a strange way it was expressed in 3 cases of
the surviving patients but only in 2 of the 3
(66%) cases who died from PBL. 
Recently,  it  has  been  suggested  that  the
expression of a germinal center (GC) pheno-
type  may  be  a  favorable  prognostic  factor.
21
Rearrangement  of  the  Bcl-6  locus  at  3q27
seems to occur more frequently in extranodal
DLBCL than in node-based disease and to be
an independent poor prognostic factor in nodal
diffuse large B-cell lymphoma.
21
Expression of Bcl-6 protein has been report-
ed  to  have  an  antiapoptotic  effect  in  GC 
B cells
21 and, by analogy with Bcl-2, it may be
expected  that  expression  of  Bcl-6  protein
would be a poor prognostic factor. However,
Bcl-6, alone and in the context of a GC pheno-
type, appeared to be associated with a favor-
able prognosis. Although not statistically sig-
nificant, it is consistent with recent observa-
tions, using gene expression and microarray
technology, that Bcl-6 expression and GC dif-
ferentiation are favorable prognostic factors.
21
It is of particular interest that a significant
proportion  (32%)  of  the  cases  with  a  Bcl-6
gene rearrangement lacked expression of Bcl-
6  protein  using  immunocytochemistry.  This
lack of correlation has been reported previous-
ly
21 and  suggests  that  rearrangement  of  the
Bcl-6 gene does not directly lead to Bcl-6 pro-
tein expression in every case. 
Our results are difficult to extrapolate due
to the small number of cases. In this study, we
used  immunohistochemistry  to  define  Bcl-2
and Bcl-6 expression. Bcl-6 was negative in
patients who died of PBL, but positive in 2 of 3
surviving patients. These results indicate that
Bcl-6 could serve as a surrogate predictor for
overall  survival  of  patients  with  PBL.  This
should be investigated in a large scale study
on PBL.
Conclusions
For  patients  with  primary  lymphomatous
involvement of the breast who will classically
present with a palpable mass, screening mam-
mography appears to contribute little to their
diagnosis, and FNA or frozen section can lead
to misdiagnosis. The results of therapy did not
appear to differ significantly from the results
seen for lymphomas occuring in other sites. 
Lymphomas  of  the  breast  are  uncommon,
present generally in elderly patients and have
a bad prognosis. This potentially curable neo-
plasm with a stage-for-stage clinical outcome
similar  to  that  of  patients  with  other  lym-
phomas of similar histological type
25 is, howev-
er, often misdiagnosed. Despite a number of
recent articles on lymphomas of the breast, it
appears that these tumors continue to be con-
fused with carcinomas. 
As no pathognomonic clinical, pathological
or radiological findings differentiate PBL com-
pletely  from  adenocarcinoma,  pathologists
must  be  attuned  to  the  possibility  of  lym-
phoma, especially if the frozen section diagno-
sis of adenocarcinoma is questionable in the
operating room.
10This could save patients from
unnecessary mastectomies.
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